Myoblast transfer in Duchenne muscular dystrophy

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Muscle Biology

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration.
• Myoblast transfer therapy (MTT) has been explored as a potential treatment for DMD, aiming to replace damaged muscle fibers with healthy donor cells.

Purpose of the Study:

• To evaluate the safety and therapeutic efficiency of myoblast transfer in patients with Duchenne muscular dystrophy.
• To assess the engraftment and functional contribution of transplanted myoblasts in DMD muscle.

Main Methods:

• Eight DMD patients underwent myoblast transfer into one biceps muscle, with the contralateral biceps serving as a placebo control.
• Donor myoblasts were derived from paternal muscle biopsies, cultured, purified, and screened for contamination.
• Patients received cyclophosphamide for immunosuppression (6 or 12 months); the procedure was blinded.

Main Results:

• Myoblast transfer was found to be safe, with no serious complications reported.
• Therapeutic efficiency was poor, evidenced by minimal improvements in maximal voluntary force, dystrophin content, and MRI findings.
• No detectable donor-derived DNA or dystrophin messenger RNA was found in the injected muscle tissue.

Conclusions:

• Myoblast transfer is a safe procedure for Duchenne muscular dystrophy patients.
• Current protocols demonstrate poor therapeutic efficacy, necessitating further research into optimizing myoblast engraftment.
• Strategies such as using younger cells or employing myonecrotic and basal laminal fenestrating agents may enhance myoblast take and therapeutic outcomes.